Literature DB >> 28122306

Hydroxysafflor yellow A promotes neovascularization and cardiac function recovery through HO-1/VEGF-A/SDF-1α cascade.

Guo Wei1, Ying Yin1, Jialin Duan1, Chao Guo1, Yanrong Zhu1, Yanhua Wang1, Miaomiao Xi2, Aidong Wen3.   

Abstract

AIM: The present study was to investigate the proangiogenic and cardioprotective effects of hydroxysafflor yellow A (HSYA) against myocardial infarction (MI) injury and the underlying mechanisms.
METHODS: MI model was induced by ligation of the left coronary artery in normal and heme oxygenase-1 (HO-1) knockout mice and the ones receiving vascular endothelial growth factor-A (VEGF-A) or stromal cell-derived factor-1α (SDF-1α) antagonists. They were treated with three doses or single dose of HSYA for 28days. The cardiac function, endothelial progenitor cells (EPCs) mobilization, angiogenesis, the expression of HO-1, VEGF-A, SDF-1α and apoptosis or fibrosis related proteins in the peri-infarct area were evaluated at respective times. We further examined the effect of HSYA on EPCs CXC chemokiner receptor 4 (CXCR4) expression and the role of SDF-1α on EPCs function in vitro.
RESULTS: HSYA could dose dependently reduce left ventricular function impairment, myocardial apoptosis and fibrosis, and promote EPCs mobilization and myocardial neovascularization. Further, HO-1 knockout abolished HSYA-induced up-regulation of HO-1, VEGF-A and SDF-1α. VEGF antagonist significantly reduced HSYA-increased VEGF-A and SDF-1α levels and SDF-1 antagonist abolished HSYA-simulated up-regulation of SDF-1α. Meanwhile, HO-1 knockout, administration of VEGF and SDF-1 antibodies abrogated HSYA-promoted expression of the marker proteins of newborn microvessels and cardiac functional recovery. In vitro, HSYA dose dependently promoted (CXCR4) expression on EPCs. SDF-1α significantly accelerated EPCs function which was reversed by CXCR4 antagonist.
CONCLUSION: HSYA could promote EPCs function through the HO-1/VEGF-A/SDF-1α signaling cascade, which contributed largely to myocardial neovascularization and further improved cardiac function in MI mice.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Endothelial progenitor cells; Hydroxysafflor yellow a; Myocardial infarction; Neovascularization

Mesh:

Substances:

Year:  2017        PMID: 28122306     DOI: 10.1016/j.biopha.2017.01.074

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  9 in total

Review 1.  Natural Herbal Medicine as a Treatment Strategy for Myocardial Infarction through the Regulation of Angiogenesis.

Authors:  Mu-Xin Zhang; Yu Song; Wan-Li Xu; Ling-Xiao Zhang; Chao Li; Yun-Lun Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-12       Impact factor: 2.650

Review 2.  Pharmacological Activities of Safflower Yellow and Its Clinical Applications.

Authors:  Yan Chen; Meifeng Li; Jiayu Wen; Xiaoqi Pan; Zixin Deng; Junren Chen; Guanru Chen; Lei Yu; Yunli Tang; Gangmin Li; Xiaofang Xie; Cheng Peng
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-27       Impact factor: 2.650

3.  Classical Chinese Herbal Formulas in the Treatment of Coronary Heart Disease: A Narrative Review.

Authors:  Xin-Hui Lu; Jun Li
Journal:  Chin J Integr Med       Date:  2018-11-27       Impact factor: 1.978

4.  Nucleolin mediated pro-angiogenic role of Hydroxysafflor Yellow A in ischaemic cardiac dysfunction: Post-transcriptional regulation of VEGF-A and MMP-9.

Authors:  Jiang Zou; Nian Wang; Manting Liu; Yongping Bai; Hao Wang; Ke Liu; Huali Zhang; Xianzhong Xiao; Kangkai Wang
Journal:  J Cell Mol Med       Date:  2018-03-07       Impact factor: 5.310

5.  Hydroxysafflor yellow A protects against angiotensin II‑induced hypertrophy.

Authors:  Bin Ni; Donglai Zhou; Yunyan Jing; Shanxin Liu
Journal:  Mol Med Rep       Date:  2018-08-17       Impact factor: 2.952

6.  Neuroprotection of hydroxysafflor yellow A in experimental cerebral ischemia/reperfusion injury via metabolic inhibition of phenylalanine and mitochondrial biogenesis.

Authors:  Suning Chen; Mao Sun; Xianghui Zhao; Zhifu Yang; Wenxing Liu; Jinyi Cao; Yi Qiao; Xiaoxing Luo; Aidong Wen
Journal:  Mol Med Rep       Date:  2019-02-15       Impact factor: 2.952

7.  Hydroxysafflor Yellow A Ameliorates Myocardial Ischemia/Reperfusion Injury by Suppressing Calcium Overload and Apoptosis.

Authors:  Jingxue Ye; Ruiying Wang; Min Wang; Jianhua Fu; Qiong Zhang; Guibo Sun; Xiaobo Sun
Journal:  Oxid Med Cell Longev       Date:  2021-05-21       Impact factor: 6.543

8.  Synergistic neuroprotective effects of Danshensu and hydroxysafflor yellow A on cerebral ischemia-reperfusion injury in rats.

Authors:  Hang Xu; WenXing Liu; TianLong Liu; Ning Su; Chao Guo; XiaoNa Feng; Fang Dou; Yi Ding; Lei Shi; AiDong Wen
Journal:  Oncotarget       Date:  2017-12-15

Review 9.  Hydroxysafflor Yellow A: A Promising Therapeutic Agent for a Broad Spectrum of Diseases.

Authors:  Hui Ao; Wuwen Feng; Cheng Peng
Journal:  Evid Based Complement Alternat Med       Date:  2018-09-25       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.